Oyster Point Pharma Crecimiento futuro
Future controles de criterios 2/6
Información clave
59.5%
Tasa de crecimiento de los beneficios
58.9%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 21.1% |
Tasa de crecimiento de los ingresos | 42.9% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Nov 08Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager
Aug 17Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 14Oyster Point stock rises 11% after H.C. Wainwright begins coverage with Buy rating
Jul 18Oyster Therapeutics: State Of Business Is Confounding
Jun 30Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Dec 24Oyster Point Pharma (NASDAQ:OYST) Is In A Good Position To Deliver On Growth Plans
Oct 15Oyster Point Pharma starts enrollment in mid-stage Neurotrophic Keratopathy study
Jun 21Here's Why We're Not Too Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Situation
May 10Need To Know: Oyster Point Pharma, Inc. (NASDAQ:OYST) Insiders Have Been Buying Shares
Feb 09Oyster Point Pharma files US application for its lead program in dry eye disease
Dec 18Companies Like Oyster Point Pharma (NASDAQ:OYST) Are In A Position To Invest In Growth
Dec 18Oyster Point Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | 289 | 11 | 42 | N/A | 3 |
12/31/2024 | 184 | -50 | -33 | N/A | 3 |
12/31/2023 | 98 | -71 | -86 | N/A | 3 |
12/31/2022 | 27 | -174 | -160 | N/A | 3 |
9/30/2022 | 20 | -177 | -166 | -166 | N/A |
6/30/2022 | 32 | -158 | -142 | -141 | N/A |
3/31/2022 | 27 | -130 | -124 | -123 | N/A |
12/31/2021 | 25 | -101 | -91 | -89 | N/A |
9/30/2021 | 18 | -81 | -71 | -69 | N/A |
6/30/2021 | N/A | -79 | -72 | -70 | N/A |
3/31/2021 | N/A | -73 | -65 | -65 | N/A |
12/31/2020 | N/A | -71 | -59 | -58 | N/A |
9/30/2020 | N/A | -68 | -54 | -54 | N/A |
6/30/2020 | N/A | -63 | -52 | -51 | N/A |
3/31/2020 | N/A | -58 | -48 | -48 | N/A |
12/31/2019 | N/A | -46 | -41 | -41 | N/A |
9/30/2019 | N/A | -30 | -28 | -28 | N/A |
6/30/2019 | N/A | -25 | -25 | -25 | N/A |
3/31/2019 | N/A | -17 | -17 | -17 | N/A |
12/31/2018 | N/A | -17 | -17 | -17 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: OYST is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: OYST is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: OYST is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: OYST's revenue (42.9% per year) is forecast to grow faster than the US market (6.8% per year).
Ingresos de alto crecimiento: OYST's revenue (42.9% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if OYST's Return on Equity is forecast to be high in 3 years time